Antiamoebic drugs for treating amoebic colitis.

Area of Science:

• Infectious Diseases
• Tropical Medicine
• Clinical Pharmacology

Background:

• Entamoeba histolytica infection is prevalent in low- and middle-income countries, causing up to 100,000 deaths annually from severe amoebic colitis.
• Effective therapy is crucial to reduce morbidity, prevent complications, and limit disease transmission.

Purpose of the Study:

• To systematically evaluate the efficacy and safety of antiamoebic drugs for treating amoebic colitis.

Main Methods:

• A comprehensive literature search was conducted up to March 2018, including multiple databases and grey literature.
• Included were 41 randomized controlled trials (4999 participants) comparing antiamoebic drugs against placebo or other antiamoebic agents.
• Data on clinical and parasitological failure, relapse, and adverse events were extracted and analyzed using random-effects models.

Main Results:

• Tinidazole showed potential for greater efficacy than metronidazole in reducing clinical failure and adverse events (low to moderate certainty evidence).
• Combination therapy might be more effective than metronidazole alone for reducing parasitological failures (low certainty evidence).
• Most included trials were old, small, and had methodological limitations, with a lack of standardized outcome definitions.

Conclusions:

• Tinidazole may offer advantages over metronidazole for amoebic colitis treatment, but evidence is limited by trial quality and age.
• Combination therapy's superiority requires further investigation with high-quality trials.
• Improved diagnostic tests for Entamoeba histolytica are needed, especially in co-infected populations.